6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
COCs	NNP	cocs	cocs	coc	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
and	CC	and	and	and	N	O
stroke	VBD	stroke	stroke	stroke	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Vascular	JJ	vascular	vascular	vascular	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
COC	NNP	coc	coc	coc	N	O
users	NNS	users	user	user	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O

Irregular	JJ	irregular	irregular	irregular	N	B-AdverseReaction

uterine	JJ	uterine	uterine	uterin	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction

Breast	NNP	breast	breast	breast	N	B-AdverseReaction
tenderness	NN	tenderness	tenderness	tender	Y	I-AdverseReaction

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
are	VBP	are	are	are	N	O
headaches	NNS	headaches	headache	headach	N	B-AdverseReaction
,	,	,	,	,	N	O
irregular	JJ	irregular	irregular	irregular	N	B-AdverseReaction
uterine	NN	uterine	uterine	uterin	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
migraines	NNS	migraines	migraine	migrain	N	B-AdverseReaction
)	)	)	)	)	N	O
13%	CD	13%	13%	13%	N	O
,	,	,	,	,	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
tenderness	NN	tenderness	tenderness	tender	Y	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	I-AdverseReaction
7%	CD	7%	7%	7%	N	O
,	,	,	,	,	N	O
menstrual	JJ	menstrual	menstrual	menstrual	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
7%	CD	7%	7%	7%	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
6%	CD	6%	6%	6%	N	O
,	,	,	,	,	N	O
acne	RB	acne	acne	acn	Y	B-AdverseReaction
4%	CD	4%	4%	4%	N	O
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
.	.	.	.	.	N	O

3%	CD	3%	3%	3%	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Bayer	NNP	bayer	bayer	bayer	N	O
HealthCare	NNP	healthcare	healthcare	healthcar	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
842	CD	842	842	842	N	O
-	:	-	-	-	N	O
2937	CD	2937	2937	2937	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Contraception	NN	contraception	contraception	contracept	Y	O
and	CC	and	and	and	N	O
Heavy	NNP	heavy	heavy	heavi	N	O
Menstrual	NNP	menstrual	menstrual	menstrual	N	O
Bleeding	NNP	bleeding	bleeding	bleed	Y	O
Studies	NNS	studies	study	studi	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
131	CD	131	131	131	N	O
women	NNS	women	woman	women	N	O
,	,	,	,	,	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
54	CD	54	54	54	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
who	WP	who	who	who	N	O
took	VBD	took	took	took	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
were	VBD	were	were	were	N	O
enrolled	VBN	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
four	CD	four	four	four	N	O
clinical	JJ	clinical	clinical	clinic	N	O
phase	NN	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
867	CD	867	867	867	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
clinical	JJ	clinical	clinical	clinic	N	O
phase	NN	phase	phase	phase	N	O
3	CD	3	3	3	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
28	CD	28	28	28	N	O
cycles	NNS	cycles	cycle	cycl	N	O
with	IN	with	with	with	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
oral	JJ	oral	oral	oral	N	O
contraceptive	NN	contraceptive	contraceptive	contracept	N	O
and	CC	and	and	and	N	O
264	CD	264	264	264	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
phase	NN	phase	phase	phase	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
7	CD	7	7	7	N	O
cycles	NNS	cycles	cycle	cycl	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
heavy	JJ	heavy	heavy	heavi	N	O
,	,	,	,	,	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
frequent	JJ	frequent	frequent	frequent	N	O
menstrual	JJ	menstrual	menstrual	menstrual	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
without	IN	without	without	without	N	O
organic	JJ	organic	organic	organ	N	O
pathology	NN	pathology	pathology	patholog	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
,	,	,	,	,	N	O
14.2	CD	14.2	14.2	14.2	N	O
.	.	.	.	.	N	O
)]	NN	)]	)]	)]	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Leading	NNP	leading	leading	lead	N	O
to	TO	to	to	to	N	O
Study	NNP	study	study	studi	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
:	:	:	:	:	N	O
11.4%	CD	11.4%	11.4%	11.4%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
women	NNS	women	woman	women	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
menstrual	JJ	menstrual	menstrual	menstrual	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
metrorrhagia	NN	metrorrhagia	metrorrhagia	metrorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
menorrhagia	NN	menorrhagia	menorrhagia	menorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
menstruation	NN	menstruation	menstruation	menstruat	N	B-AdverseReaction
irregular	NN	irregular	irregular	irregular	N	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysfunctional	JJ	dysfunctional	dysfunctional	dysfunct	N	B-AdverseReaction
uterine	JJ	uterine	uterine	uterin	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
(	(	(	(	(	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
swings	NNS	swings	swing	swing	N	I-AdverseReaction
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
altered	VBD	altered	altered	alter	N	I-AdverseReaction
,	,	,	,	,	N	O
depressed	VBD	depressed	depressed	depress	N	B-AdverseReaction
mood	NN	mood	mood	mood	N	I-AdverseReaction
,	,	,	,	,	N	O
dysthymic	JJ	dysthymic	dysthymic	dysthym	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
crying	VBG	crying	cry	cri	Y	B-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
acne	NN	acne	acne	acn	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
migraines	NNS	migraines	migraine	migrain	N	B-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
(	(	(	(	(	N	O
0.7	CD	0.7	0.7	0.7	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
migraines	NNS	migraines	migraine	migrain	N	B-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
12.7%	CD	12.7%	12.7%	12.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
breast	RB	breast	breast	breast	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
or	CC	or	or	or	N	O
tenderness	NN	tenderness	tenderness	tender	Y	I-AdverseReaction
(	(	(	(	(	N	O
7.0%	CD	7.0%	7.0%	7.0%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
menstrual	JJ	menstrual	menstrual	menstrual	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
metrorrhagia	NN	metrorrhagia	metrorrhagia	metrorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
menstruation	NN	menstruation	menstruation	menstruat	N	B-AdverseReaction
irregular	NN	irregular	irregular	irregular	N	I-AdverseReaction
,	,	,	,	,	N	O
menorrhagia	NN	menorrhagia	menorrhagia	menorrhagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysfunctional	JJ	dysfunctional	dysfunctional	dysfunct	N	B-AdverseReaction
uterine	NN	uterine	uterine	uterin	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
withdrawal	NN	withdrawal	withdrawal	withdraw	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
uterine	JJ	uterine	uterine	uterin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
6.9%	CD	6.9%	6.9%	6.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
acne	RB	acne	acne	acn	Y	B-AdverseReaction
(	(	(	(	(	N	O
3.9%	CD	3.9%	3.9%	3.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
(	(	(	(	(	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
swings	NNS	swings	swing	swing	N	I-AdverseReaction
,	,	,	,	,	N	O
depressed	VBD	depressed	depressed	depress	N	B-AdverseReaction
mood	NN	mood	mood	mood	N	I-AdverseReaction
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
altered	VBD	altered	altered	alter	N	I-AdverseReaction
,	,	,	,	,	N	O
affect	JJ	affect	affect	affect	N	B-AdverseReaction
lability	NN	lability	lability	labil	N	I-AdverseReaction
,	,	,	,	,	N	O
dysthymic	JJ	dysthymic	dysthymic	dysthym	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
crying	VBG	crying	cry	cri	Y	B-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
(	(	(	(	(	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
cases	NNS	cases	case	case	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ruptured	VBD	ruptured	ruptured	ruptur	N	B-AdverseReaction
ovarian	JJ	ovarian	ovarian	ovarian	N	I-AdverseReaction
cyst	NN	cyst	cyst	cyst	Y	I-AdverseReaction
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
cases	NNS	cases	case	case	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
focal	JJ	focal	focal	focal	N	B-AdverseReaction
nodular	JJ	nodular	nodular	nodular	N	I-AdverseReaction
hyperplasia	NN	hyperplasia	hyperplasia	hyperplasia	Y	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
,	,	,	,	,	N	O
uterine	JJ	uterine	uterine	uterin	N	B-AdverseReaction
leiomyoma	NN	leiomyoma	leiomyoma	leiomyoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
cholecystitis	NN	cholecystitis	cholecystitis	cholecyst	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
chronic	JJ	chronic	chronic	chronic	N	B-AdverseReaction
acalculous	JJ	acalculous	acalculous	acalcul	N	I-AdverseReaction
cholecystitis	NN	cholecystitis	cholecystitis	cholecyst	Y	I-AdverseReaction
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Venous	JJ	venous	venous	venou	N	B-AdverseReaction
and	CC	and	and	and	N	O
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
emboli	NN	emboli	embolus	emboli	N	I-AdverseReaction
,	,	,	,	,	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
and	CC	and	and	and	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Gallbladder	NNP	gallbladder	gallbladder	gallbladd	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction

Immune	NNP	immune	immune	immun	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Fluid	NNP	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
,	,	,	,	,	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Chloasma	NNP	chloasma	chloasma	chloasma	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
nodosum	NN	nodosum	nodosum	nodosum	N	I-AdverseReaction
,	,	,	,	,	N	O
erythema	FW	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
example	NN	example	example	exampl	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
Vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
CIGARETTE	NNP	cigarette	cigarette	cigarett	N	O
SMOKING	NNP	smoking	smoking	smoke	N	O
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
CARDIOVASCULAR	NNP	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
\n\n	JJ	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
CIGARETTE	NNP	cigarette	cigarette	cigarett	N	O
SMOKING	NNP	smoking	smoking	smoke	N	O
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
CARDIOVASCULAR	NNP	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Cigarette	NNP	cigarette	cigarette	cigarett	N	O
smoking	NN	smoking	smoking	smoke	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
from	IN	from	from	from	N	O
combination	NN	combination	combination	combin	N	B-DrugClass
oral	JJ	oral	oral	oral	N	I-DrugClass
contraceptives	NNS	contraceptives	contraceptive	contracept	N	I-DrugClass
(	(	(	(	(	N	O
COC	NNP	coc	coc	coc	N	O
)	)	)	)	)	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
risk	NN	risk	risk	risk	N	O
increases	VBZ	increases	increase	increas	N	O
with	IN	with	with	with	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
over	IN	over	over	over	N	O
35	CD	35	35	35	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
cigarettes	NNS	cigarettes	cigarette	cigarett	N	O
smoked	VBN	smoked	smoked	smoke	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
this	DT	this	this	thi	N	O
reason	NN	reason	reason	reason	N	O
,	,	,	,	,	N	O
COCs	NNP	cocs	cocs	coc	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
by	IN	by	by	by	N	O
women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
over	IN	over	over	over	N	O
35	CD	35	35	35	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
smoke	NN	smoke	smoke	smoke	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
CIGARETTE	NNP	cigarette	cigarette	cigarett	N	O
SMOKING	NNP	smoking	smoking	smoke	N	O
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
CARDIOVASCULAR	NNP	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
EVENTS	NNP	events	event	event	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
over	IN	over	over	over	N	O
35	CD	35	35	35	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
who	WP	who	who	who	N	O
smoke	VBD	smoke	smoke	smoke	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Cigarette	NNP	cigarette	cigarette	cigarett	N	O
smoking	NN	smoking	smoking	smoke	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
from	IN	from	from	from	N	O
combination	NN	combination	combination	combin	N	B-DrugClass
oral	JJ	oral	oral	oral	N	I-DrugClass
contraceptive	NN	contraceptive	contraceptive	contracept	N	I-DrugClass
(	(	(	(	(	N	O
COC	NNP	coc	coc	coc	N	O
)	)	)	)	)	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Vascular	JJ	vascular	vascular	vascular	N	B-AdverseReaction
risks	NNS	risks	risk	risk	N	I-AdverseReaction
:	:	:	:	:	N	O
Stop	NNP	stop	stop	stop	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	I-AdverseReaction
event	NN	event	event	event	N	O
occurs	NNS	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

Stop	NNP	stop	stop	stop	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
before	RB	before	before	befor	N	O
and	CC	and	and	and	N	O
through	IN	through	through	through	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
major	JJ	major	major	major	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
.	.	.	.	.	N	O

Start	NNP	start	start	start	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
no	RB	no	no	no	N	O
earlier	JJR	earlier	earlier	earlier	N	O
than	IN	than	than	than	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
delivery	NN	delivery	delivery	deliveri	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
breastfeeding	VBG	breastfeeding	breastfeeding	breastfeed	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Liver	JJ	liver	liver	liver	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
occurs	NNS	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

High	JJ	high	high	high	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
:	:	:	:	:	N	O
Do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
for	IN	for	for	for	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
or	CC	or	or	or	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
with	IN	with	with	with	N	O
vascular	JJ	vascular	vascular	vascular	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Carbohydrate	NNP	carbohydrate	carbohydrate	carbohydr	N	B-AdverseReaction
and	CC	and	and	and	N	O
lipid	JJ	lipid	lipid	lipid	N	B-AdverseReaction
metabolic	JJ	metabolic	metabolic	metabol	N	I-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
prediabetic	JJ	prediabetic	prediabetic	prediabet	N	O
and	CC	and	and	and	N	O
diabetic	JJ	diabetic	diabetic	diabet	Y	O
women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
an	DT	an	an	an	N	O
alternate	NN	alternate	alternate	altern	N	O
contraceptive	NN	contraceptive	contraceptive	contracept	N	O
method	NN	method	method	method	N	O
for	IN	for	for	for	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction
:	:	:	:	:	N	O
Evaluate	NNP	evaluate	evaluate	evalu	N	O
significant	JJ	significant	significant	signific	N	O
change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
headaches	NNS	headaches	headache	headach	N	O
and	CC	and	and	and	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Uterine	JJ	uterine	uterine	uterin	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
:	:	:	:	:	N	O
Evaluate	NNP	evaluate	evaluate	evalu	N	O
irregular	JJ	irregular	irregular	irregular	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
or	CC	or	or	or	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

CYP3A4	JJ	cyp3a4	cyp3a4	cyp3a4	N	O
induction	NN	induction	induction	induct	N	O
:	:	:	:	:	N	O
Women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
inducers	NNS	inducers	inducer	induc	N	O
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
example	NN	example	example	exampl	N	O
,	,	,	,	,	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
,	,	,	,	,	N	O
phenytoin	NN	phenytoin	phenytoin	phenytoin	N	O
,	,	,	,	,	N	O
rifampicin	NN	rifampicin	rifampicin	rifampicin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
St	NNP	st	st	st	N	O
.	.	.	.	.	N	O

John	NNP	john	john	john	N	O
's	POS	's	's	's	N	O
wort	NN	wort	wort	wort	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
choose	VB	choose	choose	choos	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
as	IN	as	a	as	N	O
their	PRP$	their	their	their	N	O
oral	JJ	oral	oral	oral	N	O
contraceptive	NN	contraceptive	contraceptive	contracept	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
decreased	JJ	decreased	decreased	decreas	N	O
contraceptive	JJ	contraceptive	contraceptive	contracept	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
,	,	,	,	,	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Thromboembolic	NN	thromboembolic	thromboembolic	thromboembol	N	O

Disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Other	JJ	other	other	other	N	O
Vascular	NNP	vascular	vascular	vascular	N	O
Problems	NNP	problems	problem	problem	N	O

Stop	NNP	stop	stop	stop	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
an	DT	an	an	an	N	O
arterial	JJ	arterial	arterial	arteri	N	O
or	CC	or	or	or	N	O
venous	JJ	venous	venous	venou	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
event	NN	event	event	event	N	O
(	(	(	(	(	N	O
VTE	NNP	vte	vte	vte	N	O
)	)	)	)	)	N	O
occurs	VBZ	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	B-Factor
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
as	IN	as	a	as	N	O
much	JJ	much	much	much	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
COCs	NNP	cocs	cocs	coc	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
VTE	NNP	vte	vte	vte	N	B-AdverseReaction
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
using	VBG	using	using	use	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
estimated	VBN	estimated	estimated	estim	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
9	CD	9	9	9	N	O
per	IN	per	per	per	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
woman	NN	woman	woman	woman	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
VTE	NNP	vte	vte	vte	N	B-AdverseReaction
is	VBZ	is	is	is	N	O
highest	JJS	highest	highest	highest	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
year	NN	year	year	year	N	O
of	IN	of	of	of	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
large	JJ	large	large	larg	N	O
,	,	,	,	,	N	O
prospective	JJ	prospective	prospective	prospect	N	O
cohort	NN	cohort	cohort	cohort	N	O
safety	NN	safety	safety	safeti	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
various	JJ	various	various	variou	N	O
COCs	NNP	cocs	cocs	coc	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
this	DT	this	this	thi	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
in	IN	in	in	in	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
COC	NN	coc	coc	coc	N	O
users	NNS	users	user	user	N	O
,	,	,	,	,	N	O
is	VBZ	is	is	is	N	O
greatest	JJS	greatest	greatest	greatest	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
COC	NNP	coc	coc	coc	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
this	DT	this	this	thi	N	O
safety	NN	safety	safety	safeti	N	O
study	NN	study	study	studi	N	O
indicate	VBP	indicate	indicate	indic	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
greatest	JJS	greatest	greatest	greatest	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
VTE	NNP	vte	vte	vte	N	B-AdverseReaction
is	VBZ	is	is	is	N	O
present	JJ	present	present	present	N	O
after	IN	after	after	after	N	O
initially	RB	initially	initially	initi	N	O
starting	VBG	starting	starting	start	N	O
a	DT	a	a	a	N	O
COC	NNP	coc	coc	coc	N	B-DrugClass
or	CC	or	or	or	N	O
restarting	VBG	restarting	restarting	restart	N	O
(	(	(	(	(	N	O
following	VBG	following	following	follow	N	O
a	DT	a	a	a	N	O
4	CD	4	4	4	N	O
week	NN	week	week	week	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
pill	NN	pill	pill	pill	N	O
-	:	-	-	-	N	O
free	JJ	free	free	free	N	O
interval	NN	interval	interval	interv	N	O
)	)	)	)	)	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
different	JJ	different	different	differ	N	O
COC	NNP	coc	coc	coc	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
also	RB	also	also	also	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thromboses	NNS	thromboses	thromboses	thrombos	N	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
strokes	NNS	strokes	stroke	stroke	N	B-AdverseReaction
and	CC	and	and	and	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarctions	NNS	infarctions	infarction	infarct	N	I-AdverseReaction
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
oral	JJ	oral	oral	oral	N	B-DrugClass
contraceptives	NNS	contraceptives	contraceptive	contracept	N	I-DrugClass
gradually	RB	gradually	gradually	gradual	N	O
disappears	NNS	disappears	disappears	disappear	N	O
after	IN	after	after	after	N	O
COC	NNP	coc	coc	coc	N	O
use	NN	use	use	use	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
feasible	JJ	feasible	feasible	feasibl	N	O
,	,	,	,	,	N	O
stop	JJ	stop	stop	stop	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
before	RB	before	before	befor	N	O
and	CC	and	and	and	N	O
through	IN	through	through	through	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
major	JJ	major	major	major	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
surgeries	NNS	surgeries	surgery	surgeri	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
an	DT	an	an	an	N	O
elevated	VBN	elevated	elevated	elev	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	O
.	.	.	.	.	N	O

Start	NNP	start	start	start	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
no	RB	no	no	no	N	O
earlier	JJR	earlier	earlier	earlier	N	O
than	IN	than	than	than	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
delivery	NN	delivery	delivery	deliveri	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
breastfeeding	VBG	breastfeeding	breastfeeding	breastfeed	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
postpartum	NN	postpartum	postpartum	postpartum	N	O
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	O
decreases	VBZ	decreases	decrease	decreas	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
third	JJ	third	third	third	N	O
postpartum	NN	postpartum	postpartum	postpartum	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
whereas	VBP	whereas	whereas	wherea	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
ovulation	NN	ovulation	ovulation	ovul	N	O
increases	NNS	increases	increase	increas	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
third	JJ	third	third	third	N	O
postpartum	NN	postpartum	postpartum	postpartum	N	O
week	NN	week	week	week	N	O
.	.	.	.	.	N	O

COCs	NNS	cocs	cocs	coc	N	B-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
both	DT	both	both	both	N	O
the	DT	the	the	the	N	O
relative	NN	relative	relative	rel	N	O
and	CC	and	and	and	N	O
attributable	JJ	attributable	attributable	attribut	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
and	CC	and	and	and	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
strokes	NNS	strokes	stroke	stroke	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
general	JJ	general	general	gener	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
is	VBZ	is	is	is	N	O
greatest	JJS	greatest	greatest	greatest	N	O
among	IN	among	among	among	N	O
older	JJR	older	older	older	N	O
(	(	(	(	(	N	O
35	CD	35	35	35	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
also	RB	also	also	also	N	O
smoke	VBD	smoke	smoke	smoke	N	O
.	.	.	.	.	N	O

COCs	NNP	cocs	cocs	coc	N	B-DrugClass
also	RB	also	also	also	N	O
increase	VBD	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
underlying	VBG	underlying	underlying	underli	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Oral	JJ	oral	oral	oral	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Stop	NNP	stop	stop	stop	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
unexplained	JJ	unexplained	unexplained	unexplain	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
,	,	,	,	,	N	O
proptosis	NN	proptosis	proptosis	proptosi	Y	O
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	O
,	,	,	,	,	N	O
papilledema	NN	papilledema	papilledema	papilledema	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
retinal	JJ	retinal	retinal	retin	N	O
vascular	JJ	vascular	vascular	vascular	N	O
lesions	NNS	lesions	lesion	lesion	N	O
.	.	.	.	.	N	O

Evaluate	NNP	evaluate	evaluate	evalu	N	O
for	IN	for	for	for	N	O
retinal	JJ	retinal	retinal	retin	N	O
vein	NN	vein	vein	vein	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	O
immediately	RB	immediately	immediately	immedi	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

5.2	CD	5.2	5.2	5.2	N	O
Carcinoma	NNP	carcinoma	carcinoma	carcinoma	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Breasts	NNS	breasts	breast	breast	N	O
and	CC	and	and	and	N	O
Reproductive	JJ	reproductive	reproductive	reproduct	N	O
Organs	NNS	organs	organ	organ	N	O

Women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
currently	RB	currently	currently	current	N	O
have	VBP	have	have	have	N	O
or	CC	or	or	or	N	O
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
breast	VBN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
because	IN	because	because	becaus	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
hormonally	RB	hormonally	hormonally	hormon	N	O
-	:	-	-	-	N	O
sensitive	JJ	sensitive	sensitive	sensit	N	O
tumor	NN	tumor	tumor	tumor	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
substantial	JJ	substantial	substantial	substanti	N	O
evidence	NN	evidence	evidence	evid	N	O
that	IN	that	that	that	N	O
COCs	NNP	cocs	cocs	coc	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	B-Negation
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
some	DT	some	some	some	N	O
past	JJ	past	past	past	N	O
studies	NNS	studies	study	studi	N	O
have	VBP	have	have	have	N	O
suggested	VBN	suggested	suggested	suggest	N	O
that	IN	that	that	that	N	O
COCs	NNP	cocs	cocs	coc	N	O
might	MD	might	might	might	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
,	,	,	,	,	N	O
more	RBR	more	more	more	N	O
recent	JJ	recent	recent	recent	N	O
studies	NNS	studies	study	studi	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	B-Negation
confirmed	VBN	confirmed	confirmed	confirm	N	I-Negation
such	JJ	such	such	such	N	O
findings	NNS	findings	finding	find	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
studies	NNS	studies	study	studi	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
are	VBP	are	are	are	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
cervical	JJ	cervical	cervical	cervic	N	B-AdverseReaction
cancer	NN	cancer	cancer	cancer	Y	I-AdverseReaction
or	CC	or	or	or	N	O
intraepithelial	JJ	intraepithelial	intraepithelial	intraepitheli	N	I-AdverseReaction
neoplasia	NN	neoplasia	neoplasia	neoplasia	N	I-AdverseReaction
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
controversy	NN	controversy	controversy	controversi	N	O
about	IN	about	about	about	N	O
the	DT	the	the	the	N	O
extent	NN	extent	extent	extent	N	O
to	TO	to	to	to	N	O
which	WDT	which	which	which	N	O
these	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
differences	NNS	differences	difference	differ	N	O
in	IN	in	in	in	N	O
sexual	JJ	sexual	sexual	sexual	N	O
behavior	NN	behavior	behavior	behavior	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Endometrial	JJ	endometrial	endometrial	endometri	N	O
biopsies	NNS	biopsies	biopsy	biopsi	N	O
performed	VBN	performed	performed	perform	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
subset	NN	subset	subset	subset	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
reveal	VB	reveal	reveal	reveal	N	O
any	DT	any	any	ani	N	O
unexpected	JJ	unexpected	unexpected	unexpect	N	O
or	CC	or	or	or	N	O
concerning	VBG	concerning	concerning	concern	N	O
findings	NNS	findings	finding	find	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
taking	VBG	taking	taking	take	N	O
COCs	NNP	cocs	cocs	coc	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

5.3	CD	5.3	5.3	5.3	N	O
Liver	NNP	liver	liver	liver	N	O
Disease	NNP	disease	disease	diseas	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
develops	NNS	develops	develops	develop	N	O
.	.	.	.	.	N	O

Steroid	NNP	steroid	steroid	steroid	N	O
hormones	NNS	hormones	hormone	hormon	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
poorly	RB	poorly	poorly	poorli	N	O
metabolized	VBN	metabolized	metabolized	metabol	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
liver	NN	liver	liver	liver	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Acute	NNP	acute	acute	acut	N	O
or	CC	or	or	or	N	O
chronic	JJ	chronic	chronic	chronic	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
may	MD	may	may	may	N	O
necessitate	VB	necessitate	necessitate	necessit	N	O
the	DT	the	the	the	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
COC	NNP	coc	coc	coc	N	O
use	NN	use	use	use	N	O
until	IN	until	until	until	N	O
markers	NNS	markers	marker	marker	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
return	NN	return	return	return	N	O
to	TO	to	to	to	N	O
normal	JJ	normal	normal	normal	N	O
and	CC	and	and	and	N	O
COC	NNP	coc	coc	coc	N	O
causation	NN	causation	causation	causat	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
excluded	VBN	excluded	excluded	exclud	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
adenomas	NNS	adenomas	adenoma	adenoma	N	I-AdverseReaction
are	VBP	are	are	are	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
COC	NNP	coc	coc	coc	N	B-DrugClass
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
estimate	NN	estimate	estimate	estim	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
attributable	JJ	attributable	attributable	attribut	N	O
risk	NN	risk	risk	risk	N	O
is	VBZ	is	is	is	N	O
3.3	CD	3.3	3.3	3.3	N	O
cases	NNS	cases	case	case	N	O
100	CD	100	100	100	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
COC	NNP	coc	coc	coc	N	O
users	NNS	users	user	user	N	O
.	.	.	.	.	N	O

Rupture	NN	rupture	rupture	ruptur	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hepatic	JJ	hepatic	hepatic	hepat	N	I-AdverseReaction
adenomas	NN	adenomas	adenoma	adenoma	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
death	NN	death	death	death	Y	B-AdverseReaction
through	IN	through	through	through	N	O
intra	JJ	intra	intra	intra	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
.	.	.	.	.	N	O

Studies	NNS	studies	study	studi	N	O
have	VBP	have	have	have	N	O
shown	VBN	shown	shown	shown	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
hepatocellular	JJ	hepatocellular	hepatocellular	hepatocellular	N	B-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
COC	NNP	coc	coc	coc	N	B-DrugClass
users	NNS	users	user	user	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
attributable	JJ	attributable	attributable	attribut	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
liver	NN	liver	liver	liver	N	B-AdverseReaction
cancers	NNS	cancers	cancer	cancer	N	I-AdverseReaction
in	IN	in	in	in	N	O
COC	NNP	coc	coc	coc	N	B-DrugClass
users	NNS	users	user	user	N	O
is	VBZ	is	is	is	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
per	IN	per	per	per	N	O
million	CD	million	million	million	N	O
users	NNS	users	user	user	N	O
.	.	.	.	.	N	O

Oral	NNP	oral	oral	oral	N	B-DrugClass
contraceptive	JJ	contraceptive	contraceptive	contracept	N	I-DrugClass
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
cholestasis	NN	cholestasis	cholestasis	cholestasi	Y	B-AdverseReaction
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
cholestasis	NN	cholestasis	cholestasis	cholestasi	Y	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
COC	NNP	coc	coc	coc	N	B-DrugClass
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
cholestasis	NN	cholestasis	cholestasis	cholestasi	Y	B-AdverseReaction
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
the	DT	the	the	the	N	O
condition	NN	condition	condition	condit	N	O
recur	NN	recur	recur	recur	N	O
with	IN	with	with	with	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
COC	NNP	coc	coc	coc	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
High	NNP	high	high	high	N	O
Blood	NNP	blood	blood	blood	N	O
Pressure	NN	pressure	pressure	pressur	N	O

For	IN	for	for	for	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
and	CC	and	and	and	N	O
stop	VB	stop	stop	stop	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
rises	VBZ	rises	rise	rise	N	O
significantly	RB	significantly	significantly	significantli	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
or	CC	or	or	or	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
with	IN	with	with	with	N	O
vascular	JJ	vascular	vascular	vascular	N	O
disease	NN	disease	disease	diseas	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
COCs	NNP	cocs	cocs	coc	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
taking	VBG	taking	taking	take	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
this	DT	this	this	thi	N	O
increase	NN	increase	increase	increas	N	O
is	VBZ	is	is	is	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
in	IN	in	in	in	N	O
older	JJR	older	older	older	N	O
women	NNS	women	woman	women	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
extended	JJ	extended	extended	extend	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
increases	NNS	increases	increase	increas	N	O
with	IN	with	with	with	N	O
increasing	VBG	increasing	increasing	increas	N	O
concentration	NN	concentration	concentration	concentr	N	O
of	IN	of	of	of	N	O
progestin	NN	progestin	progestin	progestin	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Gallbladder	NNP	gallbladder	gallbladder	gallbladd	N	O
Disease	NNP	disease	disease	diseas	N	O

Studies	NNS	studies	study	studi	N	O
suggest	VBP	suggest	suggest	suggest	N	O
a	DT	a	a	a	N	O
small	JJ	small	small	small	N	O
increased	JJ	increased	increased	increas	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
gallbladder	JJ	gallbladder	gallbladder	gallbladd	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
among	IN	among	among	among	N	O
COC	NNP	coc	coc	coc	N	B-DrugClass
users	NNS	users	user	user	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Carbohydrate	NNP	carbohydrate	carbohydrate	carbohydr	N	O
and	CC	and	and	and	N	O
Lipid	NNP	lipid	lipid	lipid	N	O
Metabolic	NNP	metabolic	metabolic	metabol	N	O
Effects	NNPS	effects	effect	effect	N	O

Carefully	RB	carefully	carefully	care	N	O
monitor	VB	monitor	monitor	monitor	N	O
prediabetic	JJ	prediabetic	prediabetic	prediabet	N	O
and	CC	and	and	and	N	O
diabetic	JJ	diabetic	diabetic	diabet	Y	O
women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
.	.	.	.	.	N	O

COCs	NNP	cocs	cocs	coc	N	B-DrugClass
may	MD	may	may	may	N	O
decrease	VB	decrease	decrease	decreas	N	B-AdverseReaction
glucose	JJ	glucose	glucose	glucos	Y	I-AdverseReaction
tolerance	NN	tolerance	tolerance	toler	N	I-AdverseReaction
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
fashion	NN	fashion	fashion	fashion	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
alternative	JJ	alternative	alternative	altern	N	O
contraception	NN	contraception	contraception	contracept	Y	O
for	IN	for	for	for	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
small	JJ	small	small	small	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
women	NNS	women	woman	women	N	O
will	MD	will	will	will	N	O
have	VB	have	have	have	N	O
adverse	JJ	adverse	adverse	advers	N	B-AdverseReaction
lipid	JJ	lipid	lipid	lipid	N	I-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
thereof	NN	thereof	thereof	thereof	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
when	WRB	when	when	when	N	O
using	VBG	using	using	use	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Headache	NNP	headache	headache	headach	Y	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
woman	NN	woman	woman	woman	N	O
taking	VBG	taking	taking	take	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
develops	VBZ	develops	develops	develop	N	O
new	JJ	new	new	new	N	O
headaches	NNS	headaches	headache	headach	N	B-AdverseReaction
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	I-AdverseReaction
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
severe	RB	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
the	DT	the	the	the	N	O
cause	NN	cause	cause	caus	N	O
and	CC	and	and	and	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
if	IN	if	if	if	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
migraine	NN	migraine	migraine	migrain	Y	B-AdverseReaction
during	IN	during	during	dure	N	O
COC	NNP	coc	coc	coc	N	B-DrugClass
use	NN	use	use	use	N	O
(	(	(	(	(	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
prodromal	JJ	prodromal	prodromal	prodrom	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
event	NN	event	event	event	N	I-AdverseReaction
)	)	)	)	)	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
reason	NN	reason	reason	reason	N	O
for	IN	for	for	for	N	O
immediate	JJ	immediate	immediate	immedi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
COC	NNP	coc	coc	coc	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Bleeding	NNP	bleeding	bleeding	bleed	Y	O
Irregularities	NNS	irregularities	irregularity	irregular	N	O

Breakthrough	IN	breakthrough	breakthrough	breakthrough	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
and	CC	and	and	and	N	O
spotting	VBG	spotting	spotting	spot	N	B-AdverseReaction
sometimes	RB	sometimes	sometimes	sometim	N	O
occur	VBP	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
three	CD	three	three	three	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
bleeding	JJ	bleeding	bleeding	bleed	Y	O
persists	NNS	persists	persists	persist	N	O
or	CC	or	or	or	N	O
occurs	NNS	occurs	occurs	occur	N	O
after	IN	after	after	after	N	O
previously	RB	previously	previously	previous	N	O
regular	JJ	regular	regular	regular	N	O
cycles	NNS	cycles	cycle	cycl	N	O
,	,	,	,	,	N	O
check	NN	check	check	check	N	O
for	IN	for	for	for	N	O
causes	NNS	causes	cause	caus	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
or	CC	or	or	or	N	O
malignancy	NN	malignancy	malignancy	malign	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pathology	NN	pathology	pathology	patholog	N	O
and	CC	and	and	and	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
are	VBP	are	are	are	N	O
excluded	VBN	excluded	excluded	exclud	N	O
,	,	,	,	,	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	O
irregularities	NNS	irregularities	irregularity	irregular	N	O
may	MD	may	may	may	N	O
resolve	VB	resolve	resolve	resolv	N	O
over	RP	over	over	over	N	O
time	NN	time	time	time	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
change	NN	change	change	chang	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
different	JJ	different	different	differ	N	O
COC	NNP	coc	coc	coc	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
and	CC	and	and	and	N	O
use	JJ	use	use	use	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
experience	VB	experience	experience	experi	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
patient	JJ	patient	patient	patient	N	O
diaries	NNS	diaries	diary	diari	N	O
,	,	,	,	,	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	O
occurs	NNS	occurs	occurs	occur	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
cycles	NNS	cycles	cycle	cycl	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
using	VBG	using	using	use	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
.	.	.	.	.	N	O

Pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
ruled	VBN	ruled	ruled	rule	N	O
out	RP	out	out	out	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
consecutive	JJ	consecutive	consecutive	consecut	N	O
cycles	NNS	cycles	cycle	cycl	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
women	NNS	women	woman	women	N	O
may	MD	may	may	may	N	B-Factor
encounter	VB	encounter	encounter	encount	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
oligomenorrhea	NN	oligomenorrhea	oligomenorrhea	oligomenorrhea	Y	B-AdverseReaction
after	IN	after	after	after	N	O
stopping	VBG	stopping	stopping	stop	N	O
COCs	NNP	cocs	cocs	coc	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
when	WRB	when	when	when	N	O
such	JJ	such	such	such	N	O
a	DT	a	a	a	N	O
condition	NN	condition	condition	condit	N	O
was	VBD	was	wa	wa	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existent	NN	existent	existent	exist	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
patient	JJ	patient	patient	patient	N	O
diaries	NNS	diaries	diary	diari	N	O
from	IN	from	from	from	N	O
three	CD	three	three	three	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
for	IN	for	for	for	N	O
contraception	NN	contraception	contraception	contracept	Y	O
,	,	,	,	,	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
23%	CD	23%	23%	23%	N	O
of	IN	of	of	of	N	O
women	NNS	women	woman	women	N	O
experienced	VBN	experienced	experienced	experienc	N	O
intracyclic	JJ	intracyclic	intracyclic	intracycl	N	B-AdverseReaction
bleeding	VBG	bleeding	bleeding	bleed	Y	I-AdverseReaction
per	IN	per	per	per	N	O
cycle	NN	cycle	cycle	cycl	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
COC	NNP	coc	coc	coc	N	O
Use	NNP	use	use	use	N	O
Before	IN	before	before	befor	N	O
or	CC	or	or	or	N	O
During	IN	during	during	dure	N	O
Early	JJ	early	early	earli	N	O
Pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O

Extensive	JJ	extensive	extensive	extens	N	O
epidemiological	JJ	epidemiological	epidemiological	epidemiolog	N	O
studies	NNS	studies	study	studi	N	O
have	VBP	have	have	have	N	O
revealed	VBN	revealed	revealed	reveal	N	O
no	DT	no	no	no	N	B-Negation
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
birth	NN	birth	birth	birth	N	B-AdverseReaction
defects	NNS	defects	defect	defect	N	I-AdverseReaction
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
used	VBN	used	used	use	N	O
oral	JJ	oral	oral	oral	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
.	.	.	.	.	N	O

Studies	NNS	studies	study	studi	N	O
also	RB	also	also	also	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	B-Negation
suggest	VB	suggest	suggest	suggest	N	O
a	DT	a	a	a	N	O
teratogenic	JJ	teratogenic	teratogenic	teratogen	N	B-AdverseReaction
effect	NN	effect	effect	effect	N	I-AdverseReaction
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
so	RB	so	so	so	N	O
far	RB	far	far	far	N	O
as	IN	as	a	as	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
anomalies	NNS	anomalies	anomaly	anomali	N	I-AdverseReaction
and	CC	and	and	and	N	O
limb	SYM	limb	limb	limb	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
reduction	NN	reduction	reduction	reduct	N	I-AdverseReaction
defects	NNS	defects	defect	defect	N	I-AdverseReaction
are	VBP	are	are	are	N	O
concerned	VBN	concerned	concerned	concern	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
taken	VBN	taken	taken	taken	N	O
inadvertently	RB	inadvertently	inadvertently	inadvert	N	O
during	IN	during	during	dure	N	O
early	JJ	early	early	earli	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
.	.	.	.	.	N	O

Oral	NNP	oral	oral	oral	N	O
contraceptive	NN	contraceptive	contraceptive	contracept	N	O
use	NN	use	use	use	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
oral	JJ	oral	oral	oral	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
to	TO	to	to	to	N	O
induce	VB	induce	induce	induc	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
test	NN	test	test	test	N	O
for	IN	for	for	for	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Depression	NN	depression	depression	depress	Y	O

Women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
observed	VBN	observed	observed	observ	N	O
and	CC	and	and	and	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
depression	NN	depression	depression	depress	Y	O
recurs	VBZ	recurs	recurs	recur	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
degree	NN	degree	degree	degre	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Interference	NN	interference	interference	interfer	N	O
with	IN	with	with	with	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
COCs	NNP	cocs	cocs	coc	N	O
may	MD	may	may	may	N	O
change	VB	change	change	chang	N	O
the	DT	the	the	the	N	O
results	NNS	results	result	result	N	O
of	IN	of	of	of	N	O
some	DT	some	some	some	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
tests	NNS	tests	test	test	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
coagulation	NN	coagulation	coagulation	coagul	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
lipids	NNS	lipids	lipid	lipid	Y	O
,	,	,	,	,	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
tolerance	NN	tolerance	tolerance	toler	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
binding	VBG	binding	binding	bind	N	O
proteins	NNS	proteins	protein	protein	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
on	IN	on	on	on	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
increased	JJ	increased	increased	increas	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
thyroid	NN	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
because	IN	because	because	becaus	N	O
serum	JJ	serum	serum	serum	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
binding	NN	binding	binding	bind	N	I-AdverseReaction
globulin	JJ	globulin	globulin	globulin	Y	I-AdverseReaction
increase	NN	increase	increase	increas	N	I-AdverseReaction
with	IN	with	with	with	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
COCs	NNP	cocs	cocs	coc	N	B-DrugClass
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Monitoring	NN	monitoring	monitoring	monitor	N	O

A	DT	a	a	a	N	O
woman	NN	woman	woman	woman	N	O
who	WP	who	who	who	N	O
is	VBZ	is	is	is	N	O
taking	VBG	taking	taking	take	N	O
COCs	NNP	cocs	cocs	coc	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
yearly	JJ	yearly	yearly	yearli	N	O
visit	NN	visit	visit	visit	N	O
with	IN	with	with	with	N	O
her	PRP$	her	her	her	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
check	NN	check	check	check	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
other	JJ	other	other	other	N	O
indicated	JJ	indicated	indicated	indic	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
.	.	.	.	.	N	O

5.13	CD	5.13	5.13	5.13	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O

Women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
take	VBP	take	take	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
strong	JJ	strong	strong	strong	N	O
cytochrome	JJ	cytochrome	cytochrome	cytochrom	N	O
P450	NNP	p450	p450	p450	N	O
3	CD	3	3	3	N	O
A4	NNP	a4	a4	a4	N	O
(	(	(	(	(	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
)	)	)	)	)	N	O
inducers	NNS	inducers	inducer	induc	N	O
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
example	NN	example	example	exampl	N	O
,	,	,	,	,	N	O
carbamazepine	NN	carbamazepine	carbamazepine	carbamazepin	N	O
,	,	,	,	,	N	O
phenytoin	NN	phenytoin	phenytoin	phenytoin	N	O
,	,	,	,	,	N	O
rifampicin	NN	rifampicin	rifampicin	rifampicin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
St	NNP	st	st	st	N	O
.	.	.	.	.	N	O

John	NNP	john	john	john	N	O
's	POS	's	's	's	N	O
wort	NN	wort	wort	wort	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
choose	VB	choose	choose	choos	N	O
Natazia	NNP	natazia	natazia	natazia	N	O
as	IN	as	a	as	N	O
their	PRP$	their	their	their	N	O
oral	JJ	oral	oral	oral	N	O
contraceptive	NN	contraceptive	contraceptive	contracept	N	O
while	IN	while	while	while	N	O
using	VBG	using	using	use	N	O
these	DT	these	these	these	N	O
inducers	NNS	inducers	inducer	induc	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
28	CD	28	28	28	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
inducers	NNS	inducers	inducer	induc	N	O
due	RB	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
decreased	JJ	decreased	decreased	decreas	N	O
contraceptive	JJ	contraceptive	contraceptive	contracept	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
.	.	.	.	.	N	O

[	JJ	[	[	[	N	O
See	NNP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

5.14	CD	5.14	5.14	5.14	N	O
Other	JJ	other	other	other	N	O
Conditions	NNS	conditions	condition	condit	N	O

In	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
hereditary	JJ	hereditary	hereditary	hereditari	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
,	,	,	,	,	N	O
exogenous	JJ	exogenous	exogenous	exogen	N	O
estrogens	NNS	estrogens	estrogen	estrogen	N	O
may	MD	may	may	may	N	B-Factor
induce	VB	induce	induce	induc	N	O
or	CC	or	or	or	N	O
exacerbate	VB	exacerbate	exacerbate	exacerb	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
.	.	.	.	.	N	O

Chloasma	NNP	chloasma	chloasma	chloasma	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
occasionally	RB	occasionally	occasionally	occasion	N	O
occur	VB	occur	occur	occur	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
chloasma	NN	chloasma	chloasma	chloasma	Y	O
gravidarum	NN	gravidarum	gravidarum	gravidarum	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
tendency	NN	tendency	tendency	tendenc	N	O
to	TO	to	to	to	N	O
chloasma	VB	chloasma	chloasma	chloasma	Y	O
should	MD	should	should	should	N	O
avoid	VB	avoid	avoid	avoid	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
sun	NN	sun	sun	sun	N	O
or	CC	or	or	or	N	O
ultraviolet	NN	ultraviolet	ultraviolet	ultraviolet	N	O
radiation	NN	radiation	radiation	radiat	N	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
COCs	NNP	cocs	cocs	coc	N	O
.	.	.	.	.	N	O

